Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU

2025/04/11

/uploads/image/2025/04/11/beilu-20250411.jpg

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

This indicates that the Iohexol Injection has obtained the relevant drug review and technical approvals from EU member states and is now eligible for sale in EU-approved countries. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

References

Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU

Gadobenate Dimeglumine Injection and Gadopentetate Dimeglumine Injections Proposed for Selection in Xinjiang Uygur Autonomous Region's 26-Province Alliance Centralized Volume-Based Procurement

Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.

Beijing Beilu Pharmaceutical's subsidiary, Hichi Pharmaceutical, has obtained GMP certification from the Brazilian National Health Surveillance Agency (ANVISA)

Beilu Pharmaceutical Subsidiary Hichi Pharmaceutical's Iopamidol Approved for Market Release

CPHI China 2024 Invitation

Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 21 Industry Guidelines Consensus Teaching Materials